Chapter 15. Pharmacogenomics of Dasatinib (Sprycel™)

  1. Rongshi Li and
  2. Jeffrey A. Stafford
  1. Fei Huang and
  2. Edwin A. Clark

Published Online: 28 SEP 2009

DOI: 10.1002/9780470524961.ch15

Kinase Inhibitor Drugs

Kinase Inhibitor Drugs

How to Cite

Huang, F. and Clark, E. A. (2009) Pharmacogenomics of Dasatinib (Sprycel™), in Kinase Inhibitor Drugs (eds R. Li and J. A. Stafford), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470524961.ch15

Editor Information

  1. Takeda San Diego, Inc., San Diego, CA 92121, USA

Author Information

  1. Oncology Clinical Biomarkers, Discovery Medicine & Clinical Pharmacology, Bristol-Myers Squibb Company, Princeton, NJ 08540, USA

Publication History

  1. Published Online: 28 SEP 2009
  2. Published Print: 2 OCT 2009

Book Series:

  1. Wiley Series in Drug Discovery and Development

Book Series Editors:

  1. Binghe Wang

ISBN Information

Print ISBN: 9780470278291

Online ISBN: 9780470524961



  • pharmacogenomics of dasatinib (Sprycel™);
  • Dasatinib;
  • multitargeted kinase inhibitor;
  • pharmacogenomics of dasatinib in breast cancer


This chapter contains sections titled:

  • Introduction

  • Dasatinib, a Multitargeted Kinase Inhibitor

  • Pharmacogenomics of Dasatinib in CML

  • Pharmacogenomics of Dasatinib in Breast Cancer

  • Pharmacogenomics of Dasatinib in Prostate Cancer

  • Other Factors May Affect Dasatinib Sensitivity

  • Perspective on Pharmacogenomics of Dasatinib

  • References